Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837667 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase 1 study, sponsored by Lixte Biotechnology Holdings.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01837667 is a Phase 1 study that has completed, run by Lixte Biotechnology Holdings. The registered enrollment target is 29 participants.
The verdict
NCT01837667, a Phase 1 study, has completed, sponsored by Lixte Biotechnology Holdings.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of cancer (chemotherapeutic agents). Docetaxel is a drug that has been approved for the treatment of some types of cancer; one of the trade names for docetaxel is Taxotere®. The study is in 2 parts. Part 1: Patients will receive injections of LB-100. Part 2: Patients will receive injections of LB-100 and docetaxel. This is the first study where LB-100 for Injection will be used in humans.
Interventions
- DRUG Docetaxel
- DRUG LB-100 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837667
The ClinicalTrials.gov registry entry for NCT01837667 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lixte Biotechnology Holdings, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01837667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01837667 about?
NCT01837667 is a clinical study titled "Phase I Study of LB-100 With Docetaxel in Solid Tumors". The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs a...
What is the current status of trial NCT01837667?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-02. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01837667?
The interventions under investigation include: Docetaxel (DRUG), LB-100 for Injection (DRUG).
Who is sponsoring clinical trial NCT01837667?
This trial is sponsored by Lixte Biotechnology Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.